Omitting Node Dissection, Adjuvant Therapy May Be Safe for Some With Stage III Melanoma

Source: Cancer Therapy Advisor, June 2022

Patients with resectable stage III melanoma who have a major pathologic response (MPR) to neoadjuvant therapy can skip therapeutic lymph node dissection (TLND) and adjuvant therapy — with their associated morbidity and toxicity — and still achieve high 2-year rates of relapse-free survival (RFS) and distant metastasis-free survival (DMFS), according to research presented at the 2022 ASCO Annual Meeting.

Investigators reported findings from PRADO, an extension cohort of the phase 2 OpACIN-neo study ( Identifier: NCT02977052) that is seeking to confirm the pathologic response rate (pRR) and safety of neoadjuvant ipilimumab 1 mg/kg plus nivolumab 3 mg/kg and to test response-driven subsequent therapy.

Eligible patients were aged 18 years and older with confirmed resectable stage III melanoma and at least 1 macroscopic lymph node metastasis, and a World Health Organization Performance Status of 0 or 1.